Maureen Early Named Vice President, Commercial Of Synthetic Biologics, Inc. (SYN)

ROCKVILLE, Md., May 7, 2015 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced Maureen Early joined the team in the newly created position of Vice President, Commercial. In her new role, Ms. Early will lead all commercial and marketing efforts for the Company's current and future product portfolio.

"Maureen has over 20 years of global and domestic strategic marketing executive experience in the pharmaceutical industry working on products from pre-launch through post-launch," said Jeff Riley, President and CEO. "During her career she has successfully launched several products, created effective anti-infective marketing programs and developed solutions to optimize brand lifecycles. Her strong track record should be of enormous benefit to Synthetic Biologics as we enter our next phase of development and growth. I look forward to working with Maureen and her team as we move our microbiome-focused product portfolio through the clinic and plan for commercial entry."

Ms. Early was President and Co-founder of Upside Endeavors, a privately owned, independent medical strategic and communications company, focused in the specialty therapeutic areas of oncology, hematology, infectious diseases and inflammation. She was responsible for business development, project execution, daily operations and was heavily involved in the launch and lifecycle planning of many products, including Prevnar 13® for adults and pediatrics, Relistor®, Tygacil®, Zyvox®, Remicade®, Stelara®, Zytiga® and Erbitux®. Prior to founding Upside Endeavors, Maureen worked for Rhone Poulenc Rorer/Aventis in various medical and marketing roles in both the areas of Infectious Disease and Oncology.

Ms. Early holds an M.B.A. in International Business from St. Joseph's University and a B.S. degree in Medical Technology with a focus in Microbiology from Marywood College, Scanton, PA.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company is developing an oral biologic to protect the gut microbiome from intravenous (IV) antibiotics for the prevention of C. difficile infection and an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

Prevnar 13® is a registered trademark of Wyeth LLC.
Relistor® is a registered trademark of Valeant Pharmaceuticals (formerly Salix Pharmaceuticals) under license from Progenics Pharmaceuticals.
Tygacil® is a registered trademark of Wyeth LLC.
Zyvox® is a registered trademark of Pfizer.
Remicade® is a registered trademark of Janssen Biotech, Inc.
Stelara® is a registered trademark of Janssen Biotech, Inc.
Zytiga® is a registered trademark of Janssen Biotech, Inc.
Erbitux® is a registered trademark of ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company.

This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our continued development pipeline, our intent to move our clinical programs forward and plan for commercial entry and the expected contributions of Ms. Early. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, a failure to successfully integrate the new management and other factors described in Synthetic Biologics' report on Form 10-K for the year ended December 31, 2014 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Logo- http://photos.prnewswire.com/prnh/20130522/MM19465LOGO

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.